Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

An Investigator Initiated Phase 2 Trial of the LSD1 Inhibitor IMG-7289 in Essential Thrombocythemia (CTMS# 19-0078)

This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.

Study Overview

• Status: Active, not recruiting
• Conditions: Thrombocythemia, Essential
• Intervention / Treatment: Drug: IMG-7289

• Study Type: Interventional
• Enrollment (Actual): 9
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Texas
    • San Antonio, Texas, United States, 78229
      • Mays Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥18 years.
• Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Arber et al., 2016).

• 3. Patients who are intolerant or resistant to hydroxyurea per ELN (European Leukemia Net) criteria, or in the Investigator's judgment are not candidates for available approved therapy. The ELN definitions of resistance/intolerance to HU (hydroxyurea) requires the fulfillment of at least one of the following criteria:

  • Platelet count greater than 600 × 109/L after 3 months of at least 2 g/day of HU (2.5 g/day in patients with a body weight over 80 kg);
  • Platelet count greater than 400 × 109/L and leukocytes less than 2.5 × 109/L or hemoglobin (Hb) less than 100 g/L at any dose of HU;
  • Presence of leg ulcers or other unacceptable mucocutaneous manifestations at any dose of HU;
  • HU-related fever.
• Requires treatment in order to lower platelet counts based on the Clinically Relevant IPSET (International Prognostic Score for Thrombosis in Essential Thrombocythemia) -Thrombosis Guidelines.
• Platelet count >450 x 109/L pre-dose Day 1.
• Peripheral blast count <10% pre-dose Day 1.
• ANC (absolute neutrophil count) ≥0.5 x 109/L pre-dose Day 1.
• Fibrosis Score ≤ grade 2, as per a slightly modified version (Arber et al., 2016) of the European Consensus Criteria for Grading Myelofibrosis, (Thiele et al., 2005).
• Life expectancy > 36 weeks.
• Able to swallow capsules.
• Amenable to spleen size determination, bone marrow evaluations, and peripheral blood sampling during the study.
• Must have discontinued ET therapy at least 2 weeks (4 weeks for interferon) prior to study drug initiation.
• Agrees to use an approved method of contraception from Screening until 28 days after last administration of the study drug. Acceptable methods of birth control include: birth control pills, depo-progesterone injections, a vaginal hormonal contraceptive ring, a barrier contraceptive such as a condom with spermicide cream or gel, diaphragms or cervical cap with spermicide cream or gel, or an intrauterine device (IUD).
• If male, agrees not to donate sperm or father a child for at least one month after the last dose of the study medication.

Exclusion Criteria:

• Greater than 3 separate transfusion episodes over the last 6 months and/or any transfusion over the last 4 weeks.
• Eastern Cooperative Oncology Group (ECOG) questionnaire score of 3 or greater.
• Currently pregnant or planning on being pregnant in the following 6 months or currently breastfeeding.
• Currently residing outside the United States.
• History of splenectomy.
• Unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1).
• Uncontrolled active infection.
• Known positive for HIV or infectious hepatitis, type A, B or C.
• Current use of monoamine oxidase A and B inhibitors (MAOIs).

• Evidence at the time of screening of increased risk of bleeding, including any of the following:

  1. Activated partial thromboplastin time (aPTT) > 1.3 x the upper limit of normal
  2. International normalized ratio (INR) >1.3 x the local upper limit of normal
  3. Known Acquired Von Willebrand's disorder.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: IMG-7289	Drug: IMG-7289; Single starting dose with individualized dose titrations throughout; Other Names: LSD1 inhibitor

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Proportion of Patients Who Achieve Complete Hematologic Remission at Week 24 Using ELN Response Criteria for ET (Barosi et al., 2013)	ELN criteria	24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Additional Therapy Period (ATP) Overall Symptom Burden	Symptom Forms will be completed by participants each week of participation in the study- even on weeks with no study visit. Symptom Form are completed at around the same time on each of the following days: Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, Day 43, Day 50, Day 57, Day 64, Day 71, Day 78, Day 85, Day 92, Day 99, Day 106, Day 113, Day 120, Day 127, Day 134, Day 141, Day 148, Day 155, Day 162 and Day 169.	24 weeks to 48 weeks (may repeat)

Collaborators and Investigators

• Sponsor: The University of Texas Health Science Center at San Antonio
• Collaborators: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
• Investigators: Principal Investigator: Zohra Nooruddin, MD, Mays Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): April 9, 2020
• Primary Completion (Actual): December 20, 2023
• Study Completion (Estimated): December 20, 2026

Study Registration Dates

• First Submitted: September 4, 2019
• First Submitted That Met QC Criteria: September 4, 2019
• First Posted (Actual): September 9, 2019

Study Record Updates

• Last Update Posted (Estimated): September 10, 2025
• Last Update Submitted That Met QC Criteria: August 25, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hematologic Diseases; Blood Coagulation Disorders; Bone Marrow Diseases; Hemorrhagic Disorders; Blood Platelet Disorders; Myeloproliferative Disorders; Hemic and Lymphatic Diseases; Thrombocytosis; Thrombocythemia, Essential; bomedemstat
• Other Study ID Numbers: CTMS# 19-0078; HSC20190791H (Other Identifier: UT Health Science Center San Antonio IRB)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No